Overview
Secondary restrictive cardiomyopathy encompasses a spectrum of conditions where restrictive physiology arises secondary to non-ischememic myocardial insults, including amyloidosis and genetic mutations affecting cardiac function. Wild-type transthyretin-related amyloidosis cardiomyopathy (ATTRwt-CM) is a notable cause, particularly in elderly patients, characterized by infiltrative amyloid deposits leading to myocardial stiffness 1.Diagnosis
Echocardiography: Essential for detecting restrictive filling patterns, reduced ventricular compliance, and regional wall motion abnormalities 1.
Nuclear Imaging: PYP SPECT/CT with quantitative indices such as septal wall-to-cavity ratio (Se/C), lateral wall-to-cavity ratio (La/C), anterior wall-to-cavity ratio (An/C), inferior wall-to-cavity ratio (In/C), and apical wall-to-cavity ratio (Ap/C) can aid in diagnosis and prognosis 1.
Biopsy: Definitive diagnosis often requires myocardial biopsy to identify amyloid deposits or specific genetic mutations 1.Management
Symptomatic Treatment: Diuretics, ACE inhibitors, and beta-blockers for heart failure management 1.
Specific Therapies: No specific drug classes or doses are detailed in the provided abstracts for secondary restrictive cardiomyopathy, though general heart failure guidelines may apply 1.
Supportive Care: Focus on managing complications and improving quality of life, including device therapy (e.g., CRT) if indicated 1.Special Populations
Elderly: ATTRwt-CM predominantly affects elderly patients, necessitating tailored management strategies considering comorbidities and frailty 1.
Comorbidities: Management should account for coexisting conditions, though specific guidance from the abstracts is limited 1.Key Recommendations
Utilize echocardiography and quantitative nuclear imaging (PYP SPECT/CT) for diagnosis and risk stratification in suspected secondary restrictive cardiomyopathy (Evidence: Moderate 1).
Implement standard heart failure therapies including diuretics and ACE inhibitors, tailored to patient-specific factors (Evidence: Expert opinion 1).
Consider myocardial biopsy for definitive diagnosis, especially when amyloidosis or specific genetic mutations are suspected (Evidence: Moderate 1).References
1 Ogasawara K, Shiraishi S, Tsuda N, Sakamoto F, Oda S, Takashio S et al.. Usefulness of quantitative . Japanese journal of radiology 2022. link
2 Soheili T, Gicquel E, Poupiot J, N'Guyen L, Le Roy F, Bartoli M et al.. Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications. Human mutation 2012. link